Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $21.6100 (-6.25%) ($21.1000 - $21.6700) on Wed. Mar. 28, 2012. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.21% (three month average) | RSI | 20 | Latest Price | $21.6100(-6.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV declines -1% a day on average for past five trading days. | Weekly Trend | VBIV declines -9.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(17%) REMX(11%) EWI(8%) XAR(8%) EEM(7%) | Factors Impacting VBIV price | VBIV will decline at least -2.605% in a week (0% probabilities). TLT(-2%) USO(1%) TIP(1%) XLU(3%) SHY(3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.605% (StdDev 5.21%) | Hourly BBV | 0 () | Intraday Trend | -0.1% | | | |
|
1 - 5 Day Possible Target | $0.07(-99.68%) | Resistance Level | $25.02 | 5 Day Moving Average | $21.97(-1.64%) | 10 Day Moving Average | $22.63(-4.51%) | 20 Day Moving Average | $25.02(-13.63%) | To recent high | -44.9% | To recent low | 2.6% | Market Cap | $4.984b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |